Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, In Patients With Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David A. Sallman, Manish Patel, Don Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, and Eytan M. Stein